Citations (44)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Eleftherios Pelechas, Paraskevi V Voulgari & Alexandros A. Drosos. (2021) Preclinical discovery and development of adalimumab for the treatment of rheumatoid arthritis. Expert Opinion on Drug Discovery 16:3, pages 227-234.
Read now
Read now
Mahtabalsadat Mirjalili, Mojtaba Shafiekhani & Afsaneh Vazin. (2020) Coronavirus Disease 2019 (COVID-19) and Transplantation: Pharmacotherapeutic Management of Immunosuppression Regimen. Therapeutics and Clinical Risk Management 16, pages 617-629.
Read now
Read now
Özgül Muştu Koryürek & Göknur Kalkan. (2016) A new alternative therapy in dermatology: tocilizumab. Cutaneous and Ocular Toxicology 35:2, pages 145-152.
Read now
Read now
Christophe Richez, Marie-Elise Truchetet, Thierry Schaeverbeke & Bernard Bannwarth. (2014) Atacicept as an investigated therapy for rheumatoid arthritis. Expert Opinion on Investigational Drugs 23:9, pages 1285-1294.
Read now
Read now
Sylvain Mathieu, Marion Couderc, Baptiste Glace, Bruno Pereira, Anne Tournadre, Jean-Jacques Dubost & Martin Soubrier. (2013) Effects of 6 months of abatacept treatment on aortic stiffness in patients with rheumatoid arthritis. Biologics: Targets and Therapy 7, pages 259-264.
Read now
Read now
Vijay Subramanian & Thalachallour Mohanakumar. (2012) Chronic rejection: a significant role for Th17-mediated autoimmune responses to self-antigens. Expert Review of Clinical Immunology 8:7, pages 663-672.
Read now
Read now
Articles from other publishers (38)
Gerd R Burmester, Vibeke Strand, Alan J Kivitz, Chih-Chi Hu, Sheldon Wang, Hubert van Hoogstraten, Gabriella L Klier & Roy Fleischmann. (2023) Long-term safety and efficacy of sarilumab with or without background csDMARDs in rheumatoid arthritis. Rheumatology.
Crossref
Crossref
Yixuan James Zheng, Wilson Ho, Martina Sanlorenzo, Igor Vujic, Adil Daud, Alain Algazi, Klemens Rappersberger & Susana Ortiz-Urda. (2022) Melanoma risk during immunomodulating treatment. Melanoma Research 32:6, pages 411-418.
Crossref
Crossref
Carlota Siljestr�m Berenguer, Gema Bonilla & Cristina Suárez-Ferrer. (2022) Intestinal disease secondary to tocilizumab. Revista Española de Enfermedades Digestivas.
Crossref
Crossref
So Hye Nam, Doo-Ho Lim, Hyun Mi Heo, Ji Seon Oh, Hyouk-Soo Kwon, Tae-Bum Kim, Soo Min Ahn, Seokchan Hong, Chang-Keun Lee, Bin Yoo & Yong-Gil Kim. (2021) Anaphylaxis to tocilizumab in patients with rheumatic disease. Immunotherapy 13:18, pages 1483-1489.
Crossref
Crossref
F. W. Kornitzky, H.-J. Langen & M. Held. (2021) Die Behandlung eines Patienten mit ausgeprägtem Zytokinsturm bei schwerer COVID-19-Pneumonie unter Einsatz von Hämoadsorption in Kombination mit der Gabe von Tocilizumab. Pneumologie 75:09, pages 644-650.
Crossref
Crossref
Jacques Morel, Anne Tournadre, Jérémie Sellam, Yoram Bouhnik, Divi Cornec, Valérie Devauchelle-Pensec, Philippe Dieudé, Philippe Goupille, Nicolas Kluger, Estibaliz Lazaro, Benoit Le Goff, Victor de Lédinghen, Thierry Lequerré, Gaëtane Nocturne, Raphaèle Seror, Marie-Elise Truchetet, Frank Verhoeven, Thao Pham & Christophe Richez. (2021) Practical management of patients on anti-IL6R therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI). Joint Bone Spine 88:4, pages 105221.
Crossref
Crossref
Milo Gatti, Michele Fusaroli, Paolo Caraceni, Elisabetta Poluzzi, Fabrizio De Ponti & Emanuel Raschi. (2020) Serious adverse events with tocilizumab: Pharmacovigilance as an aid to prioritize monitoring in COVID‐19. British Journal of Clinical Pharmacology 87:3, pages 1533-1540.
Crossref
Crossref
Daniel Aletaha, Clifton O Bingham, George Athanasios Karpouzas, Tsutomu Takeuchi, Carter Thorne, Androniki Bili, Prasheen Agarwal, Benjamin Hsu, Ravi Rao, Kurt Brown & Yoshiya Tanaka. (2021) Long-term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE). RMD Open 7:1, pages e001465.
Crossref
Crossref
Muhammad Hamdan Gul, Zin Mar Htun, Nauman Shaukat, Muhammad Imran & Ahmad Khan. (2020) Potential specific therapies in COVID-19. Therapeutic Advances in Respiratory Disease 14, pages 175346662092685.
Crossref
Crossref
Alexander Pfeil, Peter Oelzner & Peter Hellmann. (2019) The Treatment of Giant Cell Arteritis in Different Clinical Settings. Frontiers in Immunology 9.
Crossref
Crossref
Diana Rosa-Gonçalves, Miguel Bernardes & Lúcia Costa. (2018) Necrotizing fasciitis in a patient receiving tocilizumab for rheumatoid arthritis • Case report. Reumatología Clínica (English Edition) 14:3, pages 168-170.
Crossref
Crossref
Diana Rosa-Gonçalves, Miguel Bernardes & Lúcia Costa. (2018) Necrotizing fasciitis in a patient receiving tocilizumab for rheumatoid arthritis – Case report. Reumatología Clínica 14:3, pages 168-170.
Crossref
Crossref
Marc Scherlinger, Sophie Alain & Christophe Richez. (2018) Monitoring of Epstein–Barr virus (EBV)/cytomegalovirus (CMV)/varicella-zoster virus (VZV) load in patients receiving tocilizumab for rheumatoid arthritis. Joint Bone Spine 85:2, pages 259-260.
Crossref
Crossref
Timo Gaber, Martin Hahne, Cindy Strehl, Paula Hoff, Yvonne Dörffel, Eugen Feist, Gerd-Rüdiger Burmester & Frank Buttgereit. (2015) Disentangling the effects of tocilizumab on neutrophil survival and function. Immunologic Research 64:3, pages 665-676.
Crossref
Crossref
Yves-Marie Pers, Roxane Schaub, Elodie Constant, Joseph Lambert, Marie Godfrin-Valnet, Clémentine Fortunet, Waafa Bourichi, Béatrice Pallot Prades, Daniel Wendling, Philippe Gaudin, Christian Jorgensen, Jean-Francis Maillefert & Hubert Marotte. (2015) Efficacy and safety of tocilizumab in elderly patients with rheumatoid arthritis. Joint Bone Spine 82:1, pages 25-30.
Crossref
Crossref
Rainer H. Böger & Gerhard Schmidt. 2015. Arzneiverordnungs-Report 2015. Arzneiverordnungs-Report 2015
501
517
.
Feiyu Xiong, Marco Janko, Mindi Walker, Dorie Makropoulos, Daniel Weinstock, Moshe Kam & Leonid Hrebien. (2014) Analysis of cytokine release assay data using machine learning approaches. International Immunopharmacology 22:2, pages 465-479.
Crossref
Crossref
J. Pfeil, J. Grulich-Henn, D. Wenning, T. Breil, P. Gunther & T. Lutz. (2014) Multiple upper gastrointestinal perforations in a 15-year-old patient treated with tocilizumab. Rheumatology 53:9, pages 1713-1714.
Crossref
Crossref
Audrey Cayot, Davy Laroche, Anne Disson-Dautriche, Anaïs Arbault, Jean-Francis Maillefert & Paul Ornetti. (2014) Cytochrome P450 interactions and clinical implication in rheumatology. Clinical Rheumatology 33:9, pages 1231-1238.
Crossref
Crossref
Qing Jiang. (2014) Natural forms of vitamin E: metabolism, antioxidant, and anti-inflammatory activities and their role in disease prevention and therapy. Free Radical Biology and Medicine 72, pages 76-90.
Crossref
Crossref
P. Kieffer, O. Hinschberger, E. Ciobanu, F. Jaeger-Bizet, A. Drabo, T. Mostoufizadeh & L. Martzolff. (2014) Efficacité clinique et biologique du tocilizumab au cours de la maladie de Horton : à propos de trois observations et revue de la littérature. La Revue de Médecine Interne 35:1, pages 56-59.
Crossref
Crossref
Rainer H. Böger & Gerhard Schmidt. 2014. Arzneiverordnungs- Report 2014. Arzneiverordnungs- Report 2014
491
512
.
Yun Wang & Qing Jiang. (2013) γ-Tocotrienol inhibits lipopolysaccharide-induced interlukin-6 and granulocyte colony-stimulating factor by suppressing C/EBPβ and NF-κB in macrophages. The Journal of Nutritional Biochemistry 24:6, pages 1146-1152.
Crossref
Crossref
Deborah Palmer & Yasser El Miedany. (2013) Treat-to-target: a tailored treatment approach to rheumatoid arthritis. British Journal of Nursing 22:6, pages 308-318.
Crossref
Crossref
Bernard Bannwarth, Driss Berdaï & Marie Kostine. (2013) Licensing of antirheumatic drugs: Are the EMA and FDA on the same page?. Joint Bone Spine 80:2, pages 121-123.
Crossref
Crossref
Said Younis, Itzhak Rosner, Doron Rimar, Nina Boulman, Michael Rozenbaum, Majed Odeh & Gleb Slobodin. (2013) Weight change during pharmacological blockade of interleukin-6 or tumor necrosis factor-α in patients with inflammatory rheumatic disorders: A 16-week comparative study. Cytokine 61:2, pages 353-355.
Crossref
Crossref
Said Younis, Itzhak Rosner, Doron Rimar, Nina Boulman, Michael Rozenbaum, Majed Odeh & Gleb Slobodin. (2013) Interleukin 6 Blockade–Associated Weight Gain With Abdominal Enlargement in a Patient With Rheumatoid Arthritis. JCR: Journal of Clinical Rheumatology 19:1, pages 48-49.
Crossref
Crossref
Bernard Bannwarth, Driss Berdaï & Marie Kostine. (2013) Autorisation de mise sur le marché des médicaments rhumatologiques : existe-t-il des désaccords entre EMA et FDA ?. Revue du Rhumatisme 80:1, pages 3-5.
Crossref
Crossref
Rainer H. Böger & Gerhard Schmidt. 2013. Arzneiverordnungs-Report 2013. Arzneiverordnungs-Report 2013
435
455
.
Michiel Bonny, Veronique Buyse & Erwin Suys. (2012) Rapidly progressive malignant melanoma in a patient treated with tocilizumab. Journal of the American Academy of Dermatology 67:2, pages e78-e79.
Crossref
Crossref
Peter J Bugelski & Pauline L Martin. (2012) Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets. British Journal of Pharmacology 166:3, pages 823-846.
Crossref
Crossref
M. G. H. van de Sande & E. R. van Slobbe-Bijlsma. (2011) Necrotizing fasciitis in a rheumatoid arthritis patient treated with tocilizumab. Rheumatology 51:3, pages 577-578.
Crossref
Crossref
. (2012) Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. The Lancet 379:9822, pages 1205-1213.
Crossref
Crossref
Ulrich Schwabe & Dieter PaffrathRainer H. Böger & Gerhard Schmidt. 2012. Arzneiverordnungs-Report 2012. Arzneiverordnungs-Report 2012
447
467
.
D. Focosi, F. Maggi, M. Pistello, U. Boggi & F. Scatena. (2011) Immunosuppressive monoclonal antibodies: current and next generation. Clinical Microbiology and Infection 17:12, pages 1759-1768.
Crossref
Crossref
Robert S. Woodrick & Eric M. Ruderman. (2011) Safety of biologic therapy in rheumatoid arthritis. Nature Reviews Rheumatology 7:11, pages 639-652.
Crossref
Crossref
SAVINO SCIASCIA, DANIELA ROSSI & DARIO ROCCATELLO. (2011) Interleukin 6 Blockade as Steroid-sparing Treatment for 2 Patients with Giant Cell Arteritis: Figure 1.. The Journal of Rheumatology 38:9, pages 2080-2081.
Crossref
Crossref
Rainer H. Böger & Gerhard Schmidt. 2011. Arzneiverordnungs-Report 2011. Arzneiverordnungs-Report 2011
441
461
.